N-2,1,3-benzothiadiazol-4-yl-N'-{2-[{2-[(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)amino]ethyl}(methyl)amino]ethyl}urea | 1076266-57-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: N-2,1,3-benzothiadiazol-4-yl-N'-{2-[{2-[(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)amino]ethyl}(methyl)amino]ethyl}urea
• 英文别名: 1-(2,1,3-Benzothiadiazol-4-yl)-3-[2-[2-[(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)amino]ethyl-methylamino]ethyl]urea
• CAS: 1076266-57-3
• 化学式: C₂₄H₃₄N₁₀OS
• 分子量: 510.666
• InChiKey: CIUSDBMOOYMJNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  143
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE
  申请人：Prevost Grégorie

  公开号：US20100137275A1

  公开（公告）日：2010-06-03

  The present invention relates to the novel triaminopyrimidine derivatives of formula (I) in which R1, R2, W, R3, R4, and R5 are variable groups. These products have a Cdc25-phosphatase-inhibiting activity. The invention also relates to a process for synthesizing these compounds and also to therapeutic compositions containing these products and to the use thereof as medicaments.

  本发明涉及公式（I）中的新型三氨基嘧啶衍生物，其中R1、R2、W、R3、R4和R5为可变基团。这些产物具有Cdc25磷酸酶抑制活性。该发明还涉及合成这些化合物的方法，以及含有这些产物的治疗组合物，以及将其用作药物的用途。
• DERIVES DE TRI-AMINO-PYRIMIDINE COMME INHIBITEURS DE PHOSPHATASE CDC25
  申请人：IPSEN PHARMA S.A.S.

  公开号：EP2152675A1

  公开（公告）日：2010-02-17
• [EN] TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE<br/>[FR] DERIVES DE TRI-AMINO-PYRIMIDINE COMME INHIBITEURS DE PHOSPHATASE CDC25
  申请人：SOD CONSEILS RECH APPLIC

  公开号：WO2008152223A1

  公开（公告）日：2008-12-18

  [EN] The present invention relates to novel triaminopyrimidine derivatives of formula (I) in which R1, R2, W, R3, R4, and R5 are variable groups. These products have a Cdc25-phosphatase-inhibiting activity. The invention also relates to a process for synthesizing these compounds and also to therapeutic compositions containing these products and to the use thereof as medicaments.
  [FR] La présente invention a pour objet de nouveaux dérivés de triamino-pyrimidine de formule (I) dans laquelle R1, R2, W, R3, R4, et R5 sont des groupements variables.formule (I) Ces produits ont une activité inhibitrice de phosphatases Cdc25. L'invention concerne également un procédé de synthèse de ces composés ainsi que des compositions thérapeutiques contenant ces produits et leur utilisation comme médicament.